Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data LeonaBio, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
3.79
13.3
42.8
61.5
93.8
70.7
17.5
General and administrative
1.66
6.71
21.2
32.6
33.3
26.1
16.7
Operating income
-5.45
-20
-64
-104
-125
-101
-102
Interest expense
0.35
0.37
0
Other non-operating income
-0.47
-1.28
0.33
3.22
7.64
3.96
1.24
Pre-tax income
-5.16
-20
-55
-95.8
-117
-96.9
-106
Income tax
0
Net income
-5.16
-20
-54.9
-95.6
-118
-96.9
-106
EBITDA
-5.45
-20
-63.5
-103
-124
-99.9
-101
EPS, basic
-14.49
-16.69
-14.89
-25.29
-30.89
-25.19
-24.70
EPS, diluted
-14.49
-16.69
-14.89
-25.29
-30.89
-25.19
-24.70
Shares, basic (weighted)
0.36
1.2
3.69
3.77
3.8
3.85
4.28
Shares, diluted (weighted)
0.36
1.2
3.69
3.77
3.8
3.85
4.28
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
2.06
60.6
111
96
90.6
48.4
69.3
Short-term investments
124
143
104
56.8
2.84
19.1
Other current assets
0.1
6.36
4.7
5.96
5.68
3.57
1.13
Total current assets
2.16
192
261
208
155
54.8
89.5
Property, plant and equipment
2.65
3.76
4.05
3.39
2.44
1.47
Lease right-of-use assets
0.94
1.46
1.26
1.05
0.81
0.54
Long-term investments
83.5
65.9
44.8
Other non-current assets
0.13
0.06
0.06
0.45
0.06
0.06
Total assets
2.19
280
332
258
160
58.8
92.2
Accounts payable
0.42
1.16
0.57
2.5
0.13
0.32
4.59
Accrued liabilities
0.85
3.12
8.44
8.6
18.3
12.4
4.96
Total current liabilities
1.27
4.41
9.29
21.4
28.8
13.1
47.5
Lease liabilities
0.88
1.63
1.59
1.22
0.8
0.34
Other non-current liabilities
1.4
Total liabilities
4.86
5.28
10.9
23
30.1
13.9
64.4
Paid-in capital
1.36
315
417
429
440
451
540
Retained earnings
-21.1
-41
-95.9
-192
-309
-406
-512
Other comprehensive income
0.03
-0.39
-1.96
-0.35
0
-0
Shareholders' equity
-19.7
274
321
235
130
44.8
27.8
Total equity
-19.7
274
321
235
130
44.8
27.8
Total liabilities and equity
2.19
280
332
258
160
58.8
92.2
Shares outstanding
0.36
3.25
3.74
3.79
3.82
3.9
9.34
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-5.16
-20
-54.9
-95.6
-118
-96.9
-106
Depreciation and amortization
0
0
0.48
0.85
0.97
0.97
0.97
Stock-based compensation
0.25
0.63
4.62
10.6
10.6
11
6.1
Change in payables
0.7
2.6
5.15
2.1
7.37
-5.75
-21.3
Cash from operations
-3.71
-24.1
-43.1
-72.5
-101
-97.2
-45.7
Capital expenditures
-2.32
-1.57
-1.14
-0.3
-0.03
Purchases of investments
-1
-227
-299
-95.3
-27.7
-14.1
-37.6
Sales and maturities of investments
2.5
19.1
279
154
123
69
21.7
Cash from investing
1.51
-210
-4.08
57.7
95.1
54.8
-15.9
Stock issued
90
Cash from financing
0.95
293
97.1
0.65
0.49
0.19
82.5
Net change in cash
-1.26
58.6
49.9
-14.2
-5.17
-42.1
20.8
Free cash flow
-26.4
-44.7
-73.6
-101
-97.2
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.25 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-421.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-248.6%
Net income / average total assets.
Return on invested capital (ROIC)
-7,584.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-38.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-50.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-36.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
56.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-29.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-19.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
11.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
4.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
29.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.01x
Current assets / current liabilities.
Quick ratio
6.53x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.53x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$2.61
Cash from operations / diluted weighted shares.
Book value per share
$3.57
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.91x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.91x
Market cap / tangible book value, when positive.
Earnings yield
-462.0%
Net income / market cap (the inverse of P/E).
Was LeonaBio, Inc. profitable in fiscal 2025?
No. It reported a net loss of $105.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.